GlassScriptPhysician profile
Rashmi Sharma
NPI 1083842678
$1,574.91
in general payments reported to CMS, 2019-2025
25 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $540 · 2021: $254 · 2024: $63.61 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $429.97 | 2019-2025 | Evenity, Prolia, Repatha |
| Amarin Pharma, INC. | $317.56 | 2019-2021 | |
| Novo Nordisk INC | $209.75 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.87 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $55.98 | 2024-2025 | |
| Corcept Therapeutics | $50.39 | 2025 | Korlym |
| Lilly USA, LLC | $45.74 | 2021-2025 | Zepbound |
| Pfizer INC. | $37.83 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.49 | 2020-2021 | |
| Abbvie INC. | $29.13 | 2024-2025 | |
| Astellas Pharma US INC | $28.64 | 2019 | |
| Biogen, INC. | $26.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $23.86 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.34 | 2025 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $18.79 | 2025 | Inspire |
| Abiomed | $18.76 | 2025 | |
| Exact Sciences Corporation | $17.85 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $16.53 | 2025 | Gemtesa |
| Genzyme Corporation | $16.12 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.67 | 2019 | |
| Abbott Laboratories | $15.55 | 2020 | |
| Radius Health, INC. | $14.18 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.67 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.